Zhao, Shuang
Hu, Shangying
Xu, Xiaoqian
Zhang, Xun
Pan, Qinjing
Chen, Feng
Zhao, Fanghui
Funding for this research was provided by:
Chinese Academy of Medical Science Initiative for Innovative Medicine (2016-I2M-1-019)
National Key R&D Program of China (2018YFC1315504)
Article History
Received: 9 June 2020
Accepted: 30 October 2020
First Online: 16 November 2020
Ethics approval and consent to participate
: The study protocol and informed consent were approved by the ethics committees of the Center for Disease Control and Prevention (CDC) Jiangsu Province and the Cancer Foundation of China. Before the study-specific procedures, written informed consent was obtained from each participant.
: Not applicable.
: The institutions of FHZ received grants from the GSK group of companies for the conduct of the clinical trial. The GSK group of companies had no role in the analyses, or interpretation of data, in the writing of the manuscript, or in the decision to publish the results. The other authors declare that they have no competing interests.